|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,076.00 GBX | -0.10% |
|
+0.29% | +4.16% |
| May. 20 | Berenberg Affirms Hikma Pharmaceuticals at Buy on 'Strong' Growth Outlook | MT |
| May. 20 | Kingfisher cut; Peel Hunt ups Oxford Nanopore | AN |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last hours
Enjoy this offer
* See conditions on site
| Capitalization | 6.18B 5.44B 5.07B 4.56B 8.48B 526B 9.51B 58.88B 23.12B 241B 23.16B 22.69B 880B | P/E ratio 2025 * |
13.3x | P/E ratio 2026 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise value | 7.11B 6.26B 5.83B 5.25B 9.76B 605B 10.95B 67.76B 26.6B 277B 26.65B 26.11B 1,013B | EV / Sales 2025 * |
2.15x | EV / Sales 2026 * | 1.99x |
| Free-Float |
65.88% | Yield 2025 * |
2.96% | Yield 2026 * | 3.22% |
More valuation ratios
* Estimated data
More news
Last Transcript: Hikma Pharmaceuticals PLC
More recommendations
More press releases
More news
| 1 day | -0.10% | ||
| 1 week | +0.29% | ||
| Current month | +4.58% | ||
| 1 month | +9.03% | ||
| 3 months | -10.13% | ||
| 6 months | +6.46% | ||
| Current year | +4.16% |
| 1 week | 2,048 |  | 2,108 |
| 1 month | 1,896 | | 2,114 |
| Current year | 1,751 | | 2,360 |
| 1 year | 1,751 | | 2,360 |
| 3 years | 1,174.5 | | 2,360 |
| 5 years | 1,174.5 | | 2,768 |
| 10 years | 814.2 | | 2,768 |
| Manager | Title | Age | Since |
|---|---|---|---|
Riad Mishlawi
CEO | Chief Executive Officer | 61 | 2023-08-31 |
Khalid Nabilsi
DFI | Director of Finance/CFO | 53 | 2000-12-31 |
Hill Julie
CMP | Compliance Officer | - | 2023-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 2005-10-13 | |
Said Darwazah
CHM | Chairman | 68 | 2014-05-14 |
Riad Mishlawi
BRD | Director/Board Member | 61 | 1989-12-31 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0.44% | 1,022 M€ | +18.16% | - | |
| 0.25% | 0 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.10% | +0.29% | +5.97% | +18.06% | 6.18B | ||
| -0.21% | -5.77% | -11.72% | +135.86% | 641B | ||
| +0.22% | +1.06% | +2.16% | -14.77% | 368B | ||
| +0.39% | -0.41% | +15.80% | +23.80% | 324B | ||
| -0.75% | +3.84% | -52.75% | +17.84% | 299B | ||
| +0.27% | +0.08% | +11.98% | -19.91% | 254B | ||
| -0.26% | +1.41% | -0.01% | +5.79% | 221B | ||
| +0.60% | +1.03% | -15.87% | -1.55% | 218B | ||
| -0.33% | +2.00% | -40.82% | -17.32% | 195B | ||
| -0.09% | -0.28% | -11.37% | +9.08% | 146B | ||
| Average | -0.03% | +0.33% | -9.66% | +15.69% | 267.13B | |
| Weighted average by Cap. | -0.03% | -0.52% | -10.24% | +33.17% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.3B 2.91B 2.71B 2.44B 4.54B 281B 5.09B 31.5B 12.37B 129B 12.39B 12.14B 471B | 3.46B 3.05B 2.84B 2.56B 4.75B 295B 5.33B 32.99B 12.95B 135B 12.98B 12.71B 493B |
| Net income | 463M 408M 380M 342M 636M 39.45B 713M 4.42B 1.73B 18.08B 1.74B 1.7B 66.04B | 519M 457M 426M 383M 713M 44.19B 799M 4.95B 1.94B 20.25B 1.95B 1.91B 73.98B |
| Net Debt | 932M 820M 764M 688M 1.28B 79.34B 1.43B 8.88B 3.49B 36.36B 3.49B 3.42B 133B | 707M 622M 580M 522M 971M 60.21B 1.09B 6.74B 2.65B 27.59B 2.65B 2.6B 101B |
More financial data
* Estimated data
Employees
9,500
Sector
Pharmaceuticals
Calendar
Aug. 06
- Q2 2025 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-05-23 | 2,076.00 p | -0.10% | 390,753 |
| 25-05-22 | 2,078.00 p | 0.00% | 432,182 |
| 25-05-21 | 2,078.00 p | +0.19% | 574,973 |
| 25-05-20 | 2,074.00 p | +0.29% | 642,444 |
| 25-05-19 | 2,068.00 p | -0.10% | 420,901 |
Delayed Quote London S.E., May 23, 2025 at 11:35 am EDT
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
28.02USD
Average target price
33.61USD
Spread / Average Target
+19.96%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HIK Stock
Select your edition
All financial news and data tailored to specific country editions
